Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Open
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverMXCT
HealthcareNMSUSD

MaxCyte, Inc.

$00123456789.0012345678900123456789-2.3%
52w low (est.) $0.80$1.37 52w high (est.)
Market data · updated 1h ago
Market data
Market cap
USD125.33M
52w range
USD0.64 - USD2.31
Beta
1.66
Sector
Healthcare
Data quality
83/100
Valuation
DCF fair value
USD1.57
Margin of safety
+48.8%
Quality & efficiency
Moat score
35/100
Return on equity
-21.3%
Profit margin
-121.2%
Debt / equity
0.10
Growth & analysts
Revenue growth
-7.1%
Analyst target
USD4.11
Target upside
+289.3%
Analysts
4
Run the 10-point checklist before you buy How these numbers are made

About MaxCyte, Inc.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Valuation

ValueGrowthProfitHealthIncome42QUALITY
Overall Rating
52
Hold
Hold

Derived from filed metrics · High confidence (83% of the inputs available)

Moat Score35
DCF Intrinsic Value
USD1.57+48.8% upside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
USD125.33M
P/E Ratio
N/A
Dividend Yield
0.00%
Revenue Growth
-7.1%
Profit Margin
-121.2%
ROE
-21.3%
Debt / Equity
0.10
Beta
1.66
Beaten Down
vs Healthcare sector:Moat 35 vs 7Yield 0.00% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · MXCT